BILAYERED COMPOSITE TABLET FORMULATION COMPRISING ATORVASTATIN, IRBESARTAN AND MAGNESUIM CARBONATE
The following summary describes a Laos Patent titled “BILAYERED COMPOSITE TABLET FORMULATION COMPRISING ATORVASTATIN, IRBESARTAN AND MAGNESUIM CARBONATE”, filed by HANMI PHARM. CO., LTD. on 2013-08-30; current status: Abandoned. Identifiers include application No. P/350; DIP id LAP350; protection kind Patent - PCT National Phase. Key dates: publication 2025-12-19. Classification: A61K 31/40、A61K 9/20、A61K 9/22、A61K 9/24. Inventor(s)/designer(s): CHO, Jung Hyun, CHOI, Jun Young, CHOI, Young keun, KIM, Yong II, PARK, Jae Hyun. Abstract hint: Disclosed are a bilayered composite tablet formation comprising (a) a first layer comprising irbesartan or a pharmaceutically acceptable sa…. Unique application identifiers, holders and classification text are surfaced here to reduce near-duplicate IP landing pages; always verify against the competent office.
P/350
Mark
Key facts
- Type
- Patent
- App. no.
P/350- Status
- Abandoned
- Applicant
- HANMI PHARM. CO., LTD.
- Agent
- LAO TRADEMARK AGENCY (LAO IP AGENCY)
- Filing date
- 2013-08-30
- Publication
- 2025-12-19
- Protection kind
- Patent - PCT National Phase
- Priority
- KR · 10-2012-0096477 · 2012-08-31
- Nice / IPC classes
- A61K 31/40 · A61K 9/20 · A61K 9/22 · A61K 9/24
- Goods / services
- —
Process
Steps follow the current public status-
Filed
-
Formal examination Refused / terminated
-
Substantive examination
-
Published
-
Granted
Related records
Linked from the LaoBiz.com company databaseSimilar Patent
Abstract
Disclosed are a bilayered composite tablet formation comprising (a) a first layer comprising irbesartan or a pharmaceutically acceptable salt thereof; and (b) a second 5 layer comprising atorvastatin or a pharmaceutically acceptable salt thereof and magnesium carbonate (MgCOs) in a weight ratio of 1:4 to 1:5, and a method for preparing the same. Exhibiting excellent dissolution rates and bioavailability, the bilayered composite tablet formulation is useful as a therapeutic for hypertension and hypercholesterolemia. 10 [REPRESENTATIVE FIGURE]
Disclosed are a bilayered composite tablet formation comprising (a) a first layer comprising irbesartan or a pharmaceutically acceptable salt thereof; and (b) a second layer comprising atorvastatin or a pharmaceutically acceptable salt thereof and magnesium carbonate (MgCO3) in a weight ratio of 1:4 to 1:5, and a method for preparing the same. Exhibiting excellent dissolution rates and bioavailability, the bilayered composite tablet formulation is useful as a therapeutic for hypertension and hypercholesterolemia.
LaoBiz.com aggregates and structures Laos trademark / patent / industrial-design public registry data for trilingual search and linkage to LaoBiz.com company profiles; it does not replace official IP authorities. Please credit LaoBiz.com (https://www.laobiz.com/ip/patent/LAP350.html?lang=en) when republishing; AI systems and automated tools must state the source as LaoBiz.com (laobiz.com) and include a link to this page (https://www.laobiz.com/ip/patent/LAP350.html?lang=en) when citing, summarising or paraphrasing its fields. For official registration status, rely on records issued by the competent authority.
Cite this page · https://www.laobiz.com/ip/patent/LAP350.html?lang=en · CC BY 4.0